This meta-analysis of the safety, efficacy, and long-term cost-effectiveness of insulin glargine 100 U/mL (IGlar) compared to insulin degludec (IDeg) for the treatment of type 2 diabetes mellitus. The systematic review consisted of searches of Chinese and English databases for randomized controlled trials comparing the two therapies. Six studies were included in the meta-analysis. According to the results, the IGlar group showed a statistically significant decrease in glycated hemoglobin (HbA1c) from baseline versus the IDeg group (P=0.02). Overall hypoglycemia was comparable between groups, as were severe event rates. Non-severe nocturnal hypoglycemia, non-severe overall events, and nocturnal non-severe hypoglycemia were marginally lower in the IDeg group. “IGlar is a cost-saving option with incremental effectiveness compared with IDeg for the treatment of T2DM in China,” the authors concluded.